ALTUVOCT 4 000 IU powder and solvent for solution for injection

A 12-month, interventional, open-label, phase 4 study in Europe (SHINE) to investigate the course of synovial hypertrophy as detected by joint ultrasound and MRI in patients with haemophilia A on efanesoctocog alfa prophylaxis.

A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE)